HER2-positive Clinical Trials in Beijing, Beijing Municipality
14 recruitingBeijing, Beijing Municipality, China
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.42 enrolled1 locationNCT06031584
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang171 enrolled1 locationNCT06722599
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,916 enrolled1 locationNCT06722612
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
HER2-positive Breast Cancer
Shu Wang285 enrolled1 locationNCT06711055
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
HER2-positive Breast Cancer
Shu Wang8,077 enrolled1 locationNCT06711068
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
HER2-positive Breast Cancer
Shu Wang519 enrolled1 locationNCT06700369
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
HER2-positive Breast Cancer
Shu Wang2,806 enrolled1 locationNCT06693024
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Shu Wang2,092 enrolled1 locationNCT06693037
Recruiting
Phase 2
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University18 enrolled1 locationNCT06023758
Recruiting
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
HER2-positive Breast Cancer
Peking Union Medical College Hospital300 enrolled1 locationNCT06035016
Recruiting
Phase 2
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
HER2-positive Breast Cancer
Peking University104 enrolled1 locationNCT04481932